 | | Vol. 13.13 – 25 April, 2024 |
| |
|
|
| Scientists showed that murine neuroendocrine cells in the healthy lung, trachea, and larynx had distinct biophysical properties but shared sensitivity to two commonly aspirated noxious stimuli, water, and acid.
[Science] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using a panel of Pseudomonas aeruginosa phages and human airway epithelial cells derived from a person with cystic fibrosis, the authors determined that interactions between phages and epithelial cells depend on specific phage properties as well as physiochemical features of the microenvironment.
[PLOS Biology] |
|
|
|
| Researchers explored the effects of burn pit smoke condensates on human airway epithelial cells (HAECs) to understand their impact on cellular targets in the human lung. HAECs were cultured at the air–liquid interface and exposed to burn pit waste smoke condensates.
[Chemical Research In Toxicology] |
| |
|
|
| Investigators found that pirin was upregulated in NSCLC, and its expression was positively correlated with poor prognosis. Overexpression of pirin inhibited autophagy and promoted NSCLC proliferation.
[Journal Of Proteome Research] |
|
|
|
| The authors focused on 33 genes that were regulated by m6A, m5C, or m1A (mRG), which were used to form mRG clusters and clusters of mRG differentially expressed genes clusters.
[Journal of Cellular and Molecular Medicine] |
|
|
|
| A series of 20 novel gefitinib derivatives incorporating the 1,2,3-triazole moiety were designed and synthesized. The synthesized compounds were evaluated for their potential anticancer activity against epidermal growth factor receptor wild-type human NSCLC cells and human lung adenocarcinoma cells.
[Scientific Reports] |
|
|
|
|
| Interstitial lung disease consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure.
[Jama-Journal Of The American Medical Association] |
|
|
|
|
| Genentech, announced that the US FDA has approved Alecensa® for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, as detected by an FDA-approved test.
[Genentech] |
|
|
|
|
| May 5 – 7, 2024
Novato, California, United States |
|
|
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Singapore Institute Of Technology – Singapore, Singapore |
|
|
|
| | Maynooth University – Maynooth, Ireland |
|
|
|
| | Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| | Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
